Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Introducing simulated IK1 into human iPSC-cardiomyocytes using dynamic clamp on an automated patch clamp system.

Stoelzle-Feix S, Becker N, Obergrussberger A, de Boer T, Goversen B, van Veen TA, Fertig N.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.040. Epub 2019 Oct 17. No abstract available.

PMID:
31963061
2.

A sensor based technique for pharmacological safety testing of cardiac transport proteins NCX, NaKATPase and respiratory chain complexes.

Okeyo G, Haedo R, Barthmes M, Bazzone A, Brüggemann A, George M, Stoelzle-Feix S, Fertig N.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.041. Epub 2019 Oct 17. No abstract available.

PMID:
31963060
3.

A new in vitro tool to investigate cardiac contractility under physiological mechanical conditions.

Linder P, Beckler M, Doerr L, Stoelzle-Feix S, Fertig N, Jung A, Staat M, Gossmann M.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.162. Epub 2019 Oct 17. No abstract available.

PMID:
31962939
4.

Bridging HTS Ion channel and myocyte data.

Ohtsuki A, Stoelzle-Feix S, Strassmaier T, Okeyo G, Bot C, Juhasz K, Becker N, Thomas U, Doerr L, Rapedius M, Brinkwirth N, Haarmann C, Goetze T, Beckler M, George M, Fertig N.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.184. Epub 2019 Oct 17. No abstract available.

PMID:
31962911
5.

Automated Dynamic Clamp for Simulation of IK1 in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Real Time Using Patchliner Dynamite8.

Becker N, Horváth A, De Boer T, Fabbri A, Grad C, Fertig N, George M, Obergrussberger A.

Curr Protoc Pharmacol. 2020 Mar;88(1):e70. doi: 10.1002/cpph.70.

PMID:
31868992
6.

Real-time monitoring β-lactam/β-lactamase inhibitor (BL/BLI) mixture towards the bacteria porin pathway at single molecule level.

Wang J, Fertig N, Ying YL.

Anal Bioanal Chem. 2019 Jul;411(19):4831-4837. doi: 10.1007/s00216-019-01650-3. Epub 2019 Mar 2.

PMID:
30824965
7.

A novel gain-of-function mutation of Piezo1 is functionally affirmed in red blood cells by high-throughput patch clamp.

Rotordam MG, Fermo E, Becker N, Barcellini W, Brüggemann A, Fertig N, Egée S, Rapedius M, Bianchi P, Kaestner L.

Haematologica. 2019 May;104(5):e179-e183. doi: 10.3324/haematol.2018.201160. Epub 2018 Sep 20. No abstract available.

8.

A Hybrid Model for Safety Pharmacology on an Automated Patch Clamp Platform: Using Dynamic Clamp to Join iPSC-Derived Cardiomyocytes and Simulations of Ik1 Ion Channels in Real-Time.

Goversen B, Becker N, Stoelzle-Feix S, Obergrussberger A, Vos MA, van Veen TAB, Fertig N, de Boer TP.

Front Physiol. 2018 Jan 19;8:1094. doi: 10.3389/fphys.2017.01094. eCollection 2017.

9.

An update on the advancing high-throughput screening techniques for patch clamp-based ion channel screens: implications for drug discovery.

Obergrussberger A, Goetze TA, Brinkwirth N, Becker N, Friis S, Rapedius M, Haarmann C, Rinke-Weiß I, Stölzle-Feix S, Brüggemann A, George M, Fertig N.

Expert Opin Drug Discov. 2018 Mar;13(3):269-277. doi: 10.1080/17460441.2018.1428555. Epub 2018 Jan 17. Review.

PMID:
29343120
10.

A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome.

Aggarwal R, Dhillon N, Fertig N, Koontz D, Qi Z, Oddis CV.

J Rheumatol. 2017 Feb;44(2):223-229. doi: 10.3899/jrheum.160618. Epub 2016 Dec 1.

PMID:
27909085
11.

Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes.

Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, Stoelzle-Feix S, Becker N, Fertig N, January CT, Anson BD, Ross JD.

Toxicol Sci. 2016 Nov;154(1):174-182. Epub 2016 Aug 7.

PMID:
27503387
12.

Safety pharmacology studies using EFP and impedance.

Obergrussberger A, Juhasz K, Thomas U, Stölzle-Feix S, Becker N, Dörr L, Beckler M, Bot C, George M, Fertig N.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:223-32. doi: 10.1016/j.vascn.2016.04.006. Epub 2016 Apr 12.

PMID:
27084108
13.

A biomimetic DNA-based channel for the ligand-controlled transport of charged molecular cargo across a biological membrane.

Burns JR, Seifert A, Fertig N, Howorka S.

Nat Nanotechnol. 2016 Feb;11(2):152-6. doi: 10.1038/nnano.2015.279. Epub 2016 Jan 11.

PMID:
26751170
14.

Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module.

Obergrussberger A, Brüggemann A, Goetze TA, Rapedius M, Haarmann C, Rinke I, Becker N, Oka T, Ohtsuki A, Stengel T, Vogel M, Steindl J, Mueller M, Stiehler J, George M, Fertig N.

J Lab Autom. 2016 Dec;21(6):779-793. Epub 2015 Dec 23.

PMID:
26702021
15.

Novel screening techniques for ion channel targeting drugs.

Obergrussberger A, Stölzle-Feix S, Becker N, Brüggemann A, Fertig N, Möller C.

Channels (Austin). 2015;9(6):367-75. doi: 10.1080/19336950.2015.1079675. Epub 2015 Nov 10. Review.

16.

Antibiotic translocation through porins studied in planar lipid bilayers using parallel platforms.

Weichbrodt C, Bajaj H, Baaken G, Wang J, Guinot S, Kreir M, Behrends JC, Winterhalter M, Fertig N.

Analyst. 2015 Jul 21;140(14):4874-81. doi: 10.1039/c4an02335h. Epub 2015 Apr 2.

PMID:
25834843
17.

New easy-to-use hybrid system for extracellular potential and impedance recordings.

Doerr L, Thomas U, Guinot DR, Bot CT, Stoelzle-Feix S, Beckler M, George M, Fertig N.

J Lab Autom. 2015 Apr;20(2):175-88. doi: 10.1177/2211068214562832. Epub 2014 Dec 22.

PMID:
25532527
18.

Anti-signal recognition particle autoantibody ELISA validation and clinical associations.

Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C, Qi Z, Koontz D, Levesque MC.

Rheumatology (Oxford). 2015 Jul;54(7):1194-9. doi: 10.1093/rheumatology/keu436. Epub 2014 Dec 17.

19.

Bilayer-spanning DNA nanopores with voltage-switching between open and closed state.

Seifert A, Göpfrich K, Burns JR, Fertig N, Keyser UF, Howorka S.

ACS Nano. 2015 Feb 24;9(2):1117-26. doi: 10.1021/nn5039433. Epub 2014 Dec 16.

20.

Temperature-sensitive gating of hCx26: high-resolution Raman spectroscopy sheds light on conformational changes.

Kniggendorf AK, Meinhardt-Wollweber M, Yuan X, Roth B, Seifert A, Fertig N, Zeilinger C.

Biomed Opt Express. 2014 Jun 6;5(7):2054-65. doi: 10.1364/BOE.5.002054. eCollection 2014 Jul 1.

21.

New strategies in ion channel screening for drug discovery: are there ways to improve its productivity?

Farre C, Fertig N.

Expert Opin Drug Discov. 2014 Oct;9(10):1103-7. doi: 10.1517/17460441.2014.942217. Epub 2014 Jul 25.

PMID:
25062795
22.

Automated Patch Clamp Analysis of nAChα7 and Na(V)1.7 Channels.

Obergrussberger A, Haarmann C, Rinke I, Becker N, Guinot D, Brueggemann A, Stoelzle-Feix S, George M, Fertig N.

Curr Protoc Pharmacol. 2014 Jun 16;65:11.13.1-48. doi: 10.1002/0471141755.ph1113s65.

PMID:
24934604
23.

Membrane assembly of the functional KcsA potassium channel in a vesicle-based eukaryotic cell-free translation system.

Dondapati SK, Kreir M, Quast RB, Wüstenhagen DA, Brüggemann A, Fertig N, Kubick S.

Biosens Bioelectron. 2014 Sep 15;59:174-83. doi: 10.1016/j.bios.2014.03.004. Epub 2014 Mar 27.

24.

Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.

Aggarwal R, Oddis CV, Goudeau D, Fertig N, Metes I, Stephens C, Qi Z, Koontz D, Levesque MC.

Rheumatology (Oxford). 2014 Mar;53(3):433-7. doi: 10.1093/rheumatology/ket383. Epub 2013 Nov 19.

25.

Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement.

Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucas M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, Kuwana M.

Arthritis Care Res (Hoboken). 2014 Apr;66(4):575-84. doi: 10.1002/acr.22163.

26.

Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system.

Becker N, Stoelzle S, Göpel S, Guinot D, Mumm P, Haarmann C, Malan D, Bohlen H, Kossolov E, Kettenhofen R, George M, Fertig N, Brüggemann A.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):82-7. doi: 10.1016/j.vascn.2013.03.009. Epub 2013 Apr 6.

PMID:
23567076
27.

Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, Oddis CV.

Ann Rheum Dis. 2014 Jan;73(1):227-32. doi: 10.1136/annrheumdis-2012-201800. Epub 2013 Feb 19.

28.

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group.

Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.

29.

Characterizing human ion channels in induced pluripotent stem cell-derived neurons.

Haythornthwaite A, Stoelzle S, Hasler A, Kiss A, Mosbacher J, George M, Brüggemann A, Fertig N.

J Biomol Screen. 2012 Oct;17(9):1264-72. Epub 2012 Aug 24.

PMID:
22923790
30.

A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis.

Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr.

Arthritis Rheum. 2012 Sep;64(9):2986-94. doi: 10.1002/art.34482.

31.

HTS techniques for patch clamp-based ion channel screening - advances and economy.

Farre C, Fertig N.

Expert Opin Drug Discov. 2012 Jun;7(6):515-24. doi: 10.1517/17460441.2012.682056. Epub 2012 Apr 16. Review.

PMID:
22507077
32.

Anti-PM-Scl antibody in patients with systemic sclerosis.

Koschik RW 2nd, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S12-6. Epub 2012 May 29.

PMID:
22261302
33.

Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy.

Chinoy H, Li CK, Platt H, Fertig N, Varsani H, Gunawardena H, Betteridge Z, Oddis CV, McHugh NJ, Wedderburn LR, Ollier WE, Cooper RG; UK Adult Onset Myositis Immunogenetic Consortium and UK Juvenile Dermatomyositis Research Group.

Rheumatology (Oxford). 2012 May;51(5):794-9. doi: 10.1093/rheumatology/ker379. Epub 2011 Dec 30.

34.

Green fluorescent protein changes the conductance of connexin 43 (Cx43) hemichannels reconstituted in planar lipid bilayers.

Carnarius C, Kreir M, Krick M, Methfessel C, Moehrle V, Valerius O, Brüggemann A, Steinem C, Fertig N.

J Biol Chem. 2012 Jan 20;287(4):2877-86. doi: 10.1074/jbc.M111.319871. Epub 2011 Dec 3.

35.

State-of-the-Art Automated Patch Clamp Devices: Heat Activation, Action Potentials, and High Throughput in Ion Channel Screening.

Stoelzle S, Obergrussberger A, Brüggemann A, Haarmann C, George M, Kettenhofen R, Fertig N.

Front Pharmacol. 2011 Nov 24;2:76. doi: 10.3389/fphar.2011.00076. eCollection 2011.

36.

Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction.

Stoelzle S, Haythornthwaite A, Kettenhofen R, Kolossov E, Bohlen H, George M, Brüggemann A, Fertig N.

J Biomol Screen. 2011 Sep;16(8):910-6. doi: 10.1177/1087057111413924. Epub 2011 Jul 20.

PMID:
21775699
37.

Renaissance of ion channel research and drug discovery by patch clamp automation.

Fertig N, Farre C.

Future Med Chem. 2010 May;2(5):691-5. doi: 10.4155/fmc.10.183. No abstract available.

38.

Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.

Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr.

Ann Rheum Dis. 2011 Jan;70(1):104-9. doi: 10.1136/ard.2009.127621. Epub 2010 Aug 2. Erratum in: Ann Rheum Dis. 2011 Jul;70(7):1350.

39.

Permeation of antibiotics through Escherichia coli OmpF and OmpC porins: screening for influx on a single-molecule level.

Mahendran KR, Kreir M, Weingart H, Fertig N, Winterhalter M.

J Biomol Screen. 2010 Mar;15(3):302-7. doi: 10.1177/1087057109357791. Epub 2010 Jan 19.

PMID:
20086208
40.

Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein.

Espada G, Maldonado Cocco JA, Fertig N, Oddis CV.

J Rheumatol. 2009 Nov;36(11):2547-51. doi: 10.3899/jrheum.090461. Epub 2009 Oct 15.

PMID:
19833756
41.

HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy.

Chinoy H, Payne D, Poulton KV, Fertig N, Betteridge Z, Gunawardena H, Davidson JE, Oddis CV, McHugh NJ, Wedderburn LR, Ollier WE, Cooper RG; UK Adult Onset Myositis Immunogenetic Collaboration & UK Juvenile Dermatomyositis Research Group.

Rheumatology (Oxford). 2009 Oct;48(10):1213-7. doi: 10.1093/rheumatology/kep248. Epub 2009 Aug 18.

PMID:
19690132
42.

Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis.

Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr, Feghali-Bostwick CA.

Arthritis Rheum. 2009 Jul 15;61(7):958-65. doi: 10.1002/art.24586.

43.

Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.

Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP.

Arthritis Rheum. 2009 Jul;60(7):2183-92. doi: 10.1002/art.24631.

44.

Anti-U3 RNP autoantibodies in systemic sclerosis.

Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr.

Arthritis Rheum. 2009 Apr;60(4):1112-8. doi: 10.1002/art.24409.

45.

Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy.

Chinoy H, Salway F, Fertig N, Oddis CV, Ollier WE, Cooper RG.

Rheumatology (Oxford). 2009 May;48(5):591-2. doi: 10.1093/rheumatology/kep035. Epub 2009 Mar 5. No abstract available.

PMID:
19269956
46.

The M34A mutant of Connexin26 reveals active conductance states in pore-suspending membranes.

Gassmann O, Kreir M, Ambrosi C, Pranskevich J, Oshima A, Röling C, Sosinsky G, Fertig N, Steinem C.

J Struct Biol. 2009 Oct;168(1):168-76. doi: 10.1016/j.jsb.2009.02.004. Epub 2009 Feb 21.

47.

Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology.

Farre C, Haythornthwaite A, Haarmann C, Stoelzle S, Kreir M, George M, Brüggemann A, Fertig N.

Comb Chem High Throughput Screen. 2009 Jan;12(1):24-37. Review.

PMID:
19149489
48.

Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study.

Arkachaisri T, Fertig N, Pino S, Medsger TA Jr.

J Rheumatol. 2008 Dec;35(12):2439-44. doi: 10.3899/jrheum.080098. Epub 2008 Nov 1.

PMID:
19004036
49.

Planar patch clamp: advances in electrophysiology.

Brüggemann A, Farre C, Haarmann C, Haythornthwaite A, Kreir M, Stoelzle S, George M, Fertig N.

Methods Mol Biol. 2008;491:165-76. doi: 10.1007/978-1-59745-526-8_13.

PMID:
18998092
50.

The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.

Chinoy H, Platt H, Lamb JA, Betteridge Z, Gunawardena H, Fertig N, Varsani H, Davidson J, Oddis CV, McHugh NJ, Wedderburn LR, Ollier WE, Cooper RG; UK Adult Onset Myositis Immunogenetic Collaboration and the Juvenile Dermatomyositis Research Group.

Arthritis Rheum. 2008 Oct;58(10):3247-54. doi: 10.1002/art.23900.

Supplemental Content

Loading ...
Support Center